Fred Hutchinson Cancer Center

Scientists see foam as starting point of a path to bedside gene therapy

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...
Fred Hutchinson Cancer Center

‘I can’t remember the last time I saw someone with bad gut GVHD’: BMT expert reflects on recent lifesaving successes

GVHD can range from mild and temporary to life-threatening and chronic — but the deadly, debilitating cases are rare now. As ...
Fred Hutchinson Cancer Center

Honoring years of service at Fred Hutch

On Oct. 9, 2025, Fred Hutch Cancer Center employees with decades of service were honored at a luncheon celebrating their ...
Fred Hutchinson Cancer Center

Oncology Insights with Dr. Petros Grivas - Episode 2

In this episode of the Oncology Insights Podcast, Dr. Petros Grivas welcomes Dr. Christina Rodriguez to discuss her journey ...
Fred Hutch

Fred Hutch Cancer Center clinic to be named in honor of Stuart and Molly Sloan for generous gift totaling $100 million

Stuart and Molly Sloan add to their 2022 transformational gift to boost their impact on research and care SEATTLE – July 22, 2025 – A Fred Hutch Cancer Center outpatient complex serving more than ...
Fred Hutch

Cell & Gene Therapy

Our research on cell-based therapies also includes cutting-edge immunotherapies that harness the patient’s own immune cells to fight disease, including genetic engineering of immune cells to attack ...
Fred Hutch

Value in Cancer Care Initiative (VCCI)

HICOR’s Value in Cancer Care Initiative (VCCI) engages oncology providers, patient partners, payers, health system representatives and researchers to improve the value of cancer care delivery in ...
Fred Hutch

Scott Nicholas Furlan, MD

Affiliate Professor, Herbold Computational Biology Program, Public Health Sciences Division, Fred Hutch Affiliate Professor, Herbold Computational Biology Program Public Health Sciences Division, Fred ...
Fred Hutchinson Cancer Center

Powerful purpose: Fred Hutch Obliteride raises $9.2M for cancer research

Today, Fred Hutch announced that in 2025 the Obliteride community raised $9.2 million for groundbreaking research. This amount brings Obliteride’s cumulative fundraising total to more than $67 million ...
Fred Hutchinson Cancer Center

Washington Research Foundation awards $5.2M to establish new clinical trials program

A new $5.2 million grant from the Washington Research Foundation will help develop a new clinical trials program between Fred ...
Fred Hutch

Are we doing diet and nutrition research wrong?

We’ve all seen the back and forth in the news about diet studies, even within the last few months. After a week or two, the hubbub died down, only to be replaced by a slew of fresh headlines touting a ...
Fred Hutch

Risk vs. benefit: Bisphosphonates in breast cancer

Bisphosphonates are popular bone-targeting drugs. Older people take them to prevent and treat osteoporosis. Breast cancer patients, particularly those with metastatic disease, take them to prevent and ...